224 related articles for article (PubMed ID: 32451295)
1. A new therapy for systemic sclerosis-associated interstitial lung disease.
Kondoh Y
Respir Investig; 2020 Jul; 58(4):227-229. PubMed ID: 32451295
[No Abstract] [Full Text] [Related]
2. Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis.
Lui JK; Bosch NA; Gillmeyer KR; Reardon CC
Am J Respir Crit Care Med; 2020 Sep; 202(6):878-880. PubMed ID: 32574505
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
4. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
Au K; Khanna D; Clements PJ; Furst DE; Tashkin DP
Curr Rheumatol Rep; 2009 Apr; 11(2):111-9. PubMed ID: 19296883
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease.
Gkiouras K; Grammatikopoulou MG; Simopoulou T; Daniil Z; Bogdanos DP
Clin Rheumatol; 2021 Aug; 40(8):3379-3380. PubMed ID: 34213671
[No Abstract] [Full Text] [Related]
7. David against Goliath: may we target and defeat interstitial lung disease in systemic sclerosis?
Miniati I; Conforti ML; Guiducci S; Matucci Cerinic M
Clin Exp Rheumatol; 2007; 25(2):169-71. PubMed ID: 17543137
[No Abstract] [Full Text] [Related]
8. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
9. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
Kuwana M; Azuma A
Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
[TBL] [Abstract][Full Text] [Related]
11. Interstitial Lung Disease: How Should Therapeutics Be Implemented?
Bruni C; Campochiaro C; de Vries-Bouwstra JK
Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835
[TBL] [Abstract][Full Text] [Related]
12. Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?
Duarte AC; Santos MJ; Cordeiro A
Clin Rheumatol; 2018 Apr; 37(4):1123-1127. PubMed ID: 29038968
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib for systemic sclerosis-associated interstitial lung disease.
Rahimi S
Lancet Respir Med; 2020 Feb; 8(2):136. PubMed ID: 31932219
[No Abstract] [Full Text] [Related]
15. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
Ueda T; Sakagami T; Kikuchi T; Takada T
Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
[TBL] [Abstract][Full Text] [Related]
16. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease.
Higuero Sevilla JP; Memon A; Hinchcliff M
Arthritis Res Ther; 2023 Jul; 25(1):118. PubMed ID: 37422652
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
Volkmann ER; Tashkin DP
Ann Am Thorac Soc; 2016 Nov; 13(11):2045-2056. PubMed ID: 27560196
[TBL] [Abstract][Full Text] [Related]
18. Management of systemic sclerosis-associated interstitial lung disease.
Roofeh D; Jaafar S; Vummidi D; Khanna D
Curr Opin Rheumatol; 2019 May; 31(3):241-249. PubMed ID: 30870216
[TBL] [Abstract][Full Text] [Related]
19. Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'.
Bredemeier M
Ann Rheum Dis; 2022 Dec; 81(12):e250. PubMed ID: 33023963
[No Abstract] [Full Text] [Related]
20. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.
Sabnani I; Zucker MJ; Rosenstein ED; Baran DA; Arroyo LH; Tsang P; Zubair M; Rivera V
Rheumatology (Oxford); 2009 Jan; 48(1):49-52. PubMed ID: 18815156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
